[1]姜文婷,俞 岩,殷佳辉.盐酸羟考酮缓释片口服和直肠给药治疗中重度癌痛的有效性和安全性评价[J].医学信息,2021,34(22):133-135.[doi:10.3969/j.issn.1006-1959.2021.22.041]
　JIANG Wen-ting,YU Yan,YIN Jia-hui.Evaluation of the Efficacy and Safety of Oxycodone Hydrochloride Sustained-release Tablets in the Treatment of Moderate to Severe Cancer Pain by Oral and Rectal Administration[J].Medical Information,2021,34(22):133-135.[doi:10.3969/j.issn.1006-1959.2021.22.041]
点击复制

盐酸羟考酮缓释片口服和直肠给药治疗中重度癌痛的有效性和安全性评价()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年22期
页码:
133-135
栏目:
药物与临床
出版日期:
2021-11-15

文章信息/Info

Title:
Evaluation of the Efficacy and Safety of Oxycodone Hydrochloride Sustained-release Tablets in the Treatment of Moderate to Severe Cancer Pain by Oral and Rectal Administration
文章编号:
1006-1959（2021）22-0133-03
作者:
姜文婷 ; 俞 岩; 殷佳辉
（1.佳木斯市肿瘤医院药剂科，黑龙江 佳木斯 154002；2.佳木斯大学附属第一医院胸外科，黑龙江 佳木斯 154002）
Author(s):
JIANG Wen-ting; YU Yan; YIN Jia-hui
(1.Department of Pharmacy,Jiamusi Tumor Hospital,Jiamusi 154002,Heilongjiang,China;2.Department of Thoracic Surgery,the First Affiliated Hospital of Jiamusi University,Jiamusi 154002,Heilongjiang,China)
关键词:
盐酸羟考酮缓释片; 直肠给药; 口服给药; 重度癌痛
Keywords:
Oxycodone hydrochloride sustained-release tablets; Rectal administration; Oral administration; Severe cancer pain
分类号:
R730.5
DOI:
10.3969/j.issn.1006-1959.2021.22.041
文献标志码:
A
摘要:
目的 观察盐酸羟考酮缓释片口服和直肠给药治疗中重度癌痛的效果和安全性。方法 选取2019年8月-2020年8月我院接诊的64例中重度癌痛患者为研究对象，采用随机数字表法分为对照组和观察组，各32例。对照组给予盐酸羟考酮缓释片口服治疗，观察组给予盐酸羟考酮缓释片直肠给药治疗，比较两组临床疗效、疼痛评分、疼痛控制起效时间、体力状况评分、生存质量评分及不良反应发生情况。结果 观察组总有效率为90.62%，高于对照组的87.50%，但差异无统计学意义（P＞0.05）；治疗后1、6、24 h，两组疼痛评分均低于治疗前，两组不同时间段疼痛评分比较，差异无统计学意义（P＞0.05）；观察组疼痛控制起效时间短于对照组，差异有统计学意义（P＜0.05）；两组体力状况评分、生存质量评分均高于治疗前，差异有统计学意义（P＜0.05），但两组间比较，差异无统计学意义（P＞0.05）；观察组不良反应发生率为9.37%，低于对照组的21.87%，差异有统计学意义（P＜0.05）。结论 盐酸羟考酮缓释片口服和直肠给药治疗中重度癌痛均具有良好的效果，可减轻疼痛，改善患者体力状况和生存质量。但盐酸羟考酮缓释片直肠给药不良反应少，起效快，患者耐受程度较高。
Abstract:
Objective To evaluate the efficacy and safety of oral and rectal administration of oxycodone hydrochloride sustained-release tablets in the treatment of moderate and severe cancer pain.Methods A total of 64 patients with moderate and severe cancer pain admitted to our hospital from August 2019 to August 2020 were selected as the research subjects. They were divided into control group and observation group by random number table method, with 32 cases in each group. The control group was treated with oral oxycodone hydrochloride sustained-release tablets, and the observation group was treated with rectal oxycodone hydrochloride sustained-release tablets. The clinical efficacy, pain score, onset time of pain control, physical condition score, quality of life score and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 90.62%, which was higher than 87.50% of the control group, but the difference was not statistically significant (P>0.05). At 1, 6 and 24 h after treatment, the pain scores of the two groups were lower than those before treatment, and there was no significant difference in the pain scores between the two groups at different time points (P>0.05). The onset time of pain control in the observation group was shorter than that in the control group, and the difference was statistically significant (P<0.05). The physical condition score and quality of life score of the two groups were higher than those before treatment, and the difference was statistically significant (P<0.05); while there was no significant difference between the two groups (P>0.05). The incidence of adverse reactions in the observation group was 9.37%, which was lower than 21.87% in the control group, and the difference was statistically significant (P<0.05).Conclusion Oral and rectal administration of oxycodone hydrochloride sustained-release tablets have good effects in the treatment of moderate and severe cancer pain, which can reduce pain, improve physical condition and quality of life of patients. But rectal administration of oxycodone hydrochloride sustained-release tablets has less adverse reactions, rapid onset, high tolerance.

参考文献/References:

[1]陈喜翠.盐酸羟考酮缓释片口服与直肠给药治疗癌痛临床对比观察[J].中国处方药,2015,13(8):46-47.[2]Huang Z,Liang L,Li L,et al.Opioid doses required for pain management in lung cancer patients with different cholesterol levels: negative correlation between opioid doses and cholesterol levels[J].Lipids Health Dis,2016(15):47.[3]高艳丽,张宝奇.瑞舒伐他汀对盐酸羟考酮缓释片治疗晚期非小细胞肺癌患者癌痛的增效作用和安全性研究[J].中国全科医学,2016,19(27):3265-3269.[4]王莉丽,朱志颖.盐酸羟考酮缓释片治疗中重度癌痛 50例临床观察[J].中国现代医生,2017,55(27):96-98．[5]朱荔丰.盐酸羟考酮缓释片与硫酸吗啡缓释片治疗中重度癌痛的疗效观察[J].淮海医药,2015,13(1):89-90.[6]元建华,赵清梅,廖燕,等.复方苦参注射液联合硫酸吗啡缓释片治疗中重度癌痛的临床观察[J].中国疼痛医学杂志,2015,21(1):79-80．[7]孙薏,李莉,张明慧,等.超大剂量盐酸羟考酮缓释片与硫酸吗啡缓释片治疗重度癌痛的疗效及安全性比较[J].现代肿瘤医学,2017,25(22):3683-3687．[8]Zhang SQ,He F,Chen HJ.Systematic review of the therapeutic eficacy of kudiezi injection on the adjunctive treatment of diabetic nephropathy[J].Chin J Mod Appl Pharm,2015,32(6):750-754.[9]陈思现,李汶珊.盐酸羟考酮缓释片与硫酸吗啡缓释片治疗阿片未耐受患者中、重度癌痛的效果比较[J].广东医学,2016,37(2):206-208．[10]喻超,隋成君,王秋石.盐酸羟考酮缓释片联合盐酸吗啡片用于门诊中重度癌痛患者药物初始剂量滴定的临床观察[J].中国医科大学学报,2020,49(01):71-75.[11]杨明军.盐酸羟考酮控释片不同给药方式对癌性疼痛的临床疗效比较[J].基层医学论坛,2015,18(22):2900-2901.[12]曾春生,曾红学,黄作超,等.“癌痛规范化治疗示范病房”创建前后癌痛药使用分析[J].中国癌痛医学杂志,2015,21(4):312-316．[13]饶欣,王长连,何冰冰.硫酸吗啡缓释片与盐酸羟考酮缓释片治疗癌痛的药物经济学评价[J].海峡医学,2015,27(9):233-235．[14]涂雪松,胡利霞.盐酸羟考酮缓释片与硫酸吗啡缓释片治疗晚期中重度癌痛的疗效对比[J].中国处方药,2015,13(10):88-89.[15]朱娴雅,徐秋萍,荣跃,等.盐酸羟考酮缓释片治疗中重度癌痛40例的临床观察[J].中国实用医药,2018,13(29):4-5.

相似文献/References:

[1]张 露,刘 铭,彭玉龙,等.盐酸羟考酮缓释片对急性放射性黏膜炎所致疼痛的应用效果评价[J].医学信息,2019,32(08):148.[doi:10.3969/j.issn.1006-1959.2019.08.045]
　ZHANG Lu,LIU Ming,PENG Yu-long,et al.Evaluation of the Effect of Oxycodone Hydrochloride Sustained-release Tablets on Pain Caused by Acute Radiation Mucositis[J].Medical Information,2019,32(22):148.[doi:10.3969/j.issn.1006-1959.2019.08.045]
[2]杨春霞,江期华.盐酸羟考酮缓释片与硫酸吗啡缓释片治疗阿片未耐受患者中、重度癌痛的效果比较[J].医学信息,2022,35(22):133.[doi:10.3969/j.issn.1006-1959.2022.22.031]
　YANG Chun-xia,JIANG Qi-hua.Comparison of Oxycodone Hydrochloride Sustained-release Tablets and Morphine Sulfate Sustained-release Tablets in the Treatment of Moderate and Severe Cancer Pain in Patients with Opioid Intolerance[J].Medical Information,2022,35(22):133.[doi:10.3969/j.issn.1006-1959.2022.22.031]

更新日期/Last Update: 1900-01-01